Population pharmacokinetic modeling and stochastic simulations to support pediatric dose selection of pimavanserin

Population pharmacokinetic modeling and stochastic simulations to support pediatric dose selection of pimavanserin

Conference: American College of Neuropsychopharmacology

pimavanserin-is-a-selective-serotonin-receptor-modulating-agent-with-inverse-agonist-antagonist-activity-at-the-5ht2a-receptor-and-to-a-lesser

Suppressing TGF-β activation to reduce lung fibrosis: In search for an efficacious dose regimen for alpha V integrin inhibitors

Suppressing TGF-β activation to reduce lung fibrosis: In search for an efficacious dose regimen for alpha V integrin inhibitors

Conference: ACoP
Software: IPFsym®

Elevated levels of TGF-β and specifically its activated form is regarded as one of the disease drivers in patients with idiopathic pulmonary fibrosis (IPF).

Population Pharmacokinetics Analysis for Molnupiravir in Adults with COVID-19

Population Pharmacokinetics Analysis for Molnupiravir in Adults with COVID-19

Conference: ACoP

There is an urgent need for safe and effective oral treatments for COVID-19 that reduce progression to severe illness and risk of hospitalization or death

CARDIOsym QSP model prediction of wound healing response following myocardial infarction

CARDIOsym QSP model prediction of wound healing response following myocardial infarction

Conference: ACoP
Software: CARDIOsym

Objectives: Cardiac wound healing post-myocardial infarction represents a complex balance between inflammation and fibrosis (Richardson 2017). A biphasic...

Mechanistic Modeling of Kidney-Injury Molecule 1 (KIM-1) as a biomarker for Cisplatin-Induced Acute Kidney Injury

Mechanistic Modeling of Kidney-Injury Molecule 1 (KIM-1) as a biomarker for Cisplatin-Induced Acute Kidney Injury

Conference: American Society of Nephrology (ASN) Kidney Week
Software: RENAsym®

Kidney Injury Molecule 1 (KIM-1) is a specific and sensitive biomarker for drug-induced kidney injury (AKI) prediction...

Clinical Ocular Exposure Extrapolation Using PBPK Modeling and Simulation: Levofloxacin Solution Case Study

Clinical Ocular Exposure Extrapolation Using PBPK Modeling and Simulation: Levofloxacin Solution Case Study

Conference: AAPS
Software: GastroPlus®
Division: PBPK
Therapeutic Areas: Ophthalmology

Development of generic ophthalmic drug products is challenging due to the complexity of the ocular system and a lack of sensitive testing tools to evaluate its interplay with ophthalmic formulations

Assessing the Potential for Hepatotoxicity for Combination Therapy of Valproate (VPA) and Cannabidiol (CBD) using Quantitative Systems Toxicology (QST)

Assessing the Potential for Hepatotoxicity for Combination Therapy of Valproate (VPA) and Cannabidiol (CBD) using Quantitative Systems Toxicology (QST)

Conference: AAPS
Software: DILIsym®

Highly purified cannabidiol (CBD) (approved as Epidiolex in the US) is efficacious in treating seizures associated with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), and Tuberous Sclerosis Complex (TSC).